A Resource Guide to Investing in Biotechnology
Directory - Encyclopedia - Stock Index - Drugs  

Biotech100 Stock Index

About Savient Pharmaceutical:

Savient Pharmaceuticals, Inc. is a specialty pharmaceuticals company engaged in the research, development, manufacture, and marketing of pharmaceutical products that address unmet medical needs in both niche and larger market segments.

Development, manufacture, distribution and sale of its oral liquid products are carried out through Rosemont in the United Kingdom.


Products on the Market


Oxandrin® is an oral anabolic agent indicated as adjunctive therapy to promote weight gain following weight loss due to extensive surgery, chronic infection, or severe trauma.

Bio-TropinTM, Savient’s genetically engineered human growth hormone, is indicated for the treatment of pituitary growth hormone deficiency in children.

BioLon® is a 1% solution of sodium hyaluronate used as a surgical aid to protect corneal endothelium during cataract extraction procedures, intraocular lens implantation, and anterior segment surgery

Delatestryl® is Savient’s injectable testosterone replacement therapy for the treatment of conditions associated with a deficiency or absence of endogenous testosterone (hypogonadism).

Bio-Hep-B®, the first recombinant hepatitis B vaccine

Silkis® is a vitamin D derivative for the topical treatment of psoriasis

Sodium hyaluronate for osteoarthritis



The Clinical Pipeline:

is a peptide sequence in development for the treatment of peripheral neuropathic pain, a serious and debilitating condition that usually affects the feet and legs. A Phase II human clinical trial of Prosaptide demonstrated that it effectively decreases pain associated with diabetic peripheral neuropathy without deleterious side effects. A Phase II study in HIV/AIDS neuropathic pain is in progress to supplement these findings.

is Savient’s genetically engineered polyethylene glycol (PEG) conjugate of uricase, an enzyme that converts uric acid into a highly soluble and more easily excreted product. A Phase II study of Puricase for the elimination of excess uric acid in individuals with symptomatic gout that is unresponsive to conventional treatment is in progress. Puricase has received FDA Orphan Drug designation for this indication.

FibrimageTM is a diagnostic agent for the detection of deep vein thrombosis (DVT),


More About Savient

Home Page

Key Statistics for Savient

Basic Chart for Savient

Analyst Opinion

Analysts Estimates


Biotech100 Index
· What are the Requirements to be listed in the Biotech100 Index?
· See the Biotech100 List

Sponsored Links

Clinical Trials
· What is a Clinical Trial?
·Phase I ,-- Phase II, -- PhaseIII
·What is Randomized Control?
 What is a Double Blind Experiment?
·What is the role of the FDA?


Key Biotech Terms


Biotech Resources


Investing in Stocks
· Small Cap Stocks
· Stocks and Bonds
· Biotech100 Index

Careers and Employment
· Biotechnology and Pharmaceutical
· What are the Fastest Growing Careers?




Copyright © 2005 BIOTECH100.COM. All rights reserved.